Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction

Circulation Research

Volumn 87, Issue 11, 2000, Pages 999-1005

  Oelze, Matthias ^a   Mollnau, Hanke ^a   Hoffmann, Nina ^a   Warnholtz, Ascan ^a   Bodenschatz, Martin ^a   Smolenski, Albert ^b   Walter, Ulrich ^b   Skatchkov, Mikhail ^a   Meinertz, Thomas ^a   Münzel, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

AT1 receptor blockade; cGMP dependent kinase; Hyperlipidemia; Nitric oxide; VASP

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOCHEMICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC GMP; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHOPROTEIN; PROTEIN KINASE; SERINE; SUPEROXIDE; SUPEROXIDE DISMUTASE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HYPERLIPIDEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE; VASCULAR ENDOTHELIUM;

EID: 0034711470     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.87.11.999     Document Type: Article

References (41)

1. Regulation and role of guanylate cyclase-cyclic GMP in vascular relaxation
2. Cyclic-GMP-dependent protein kinase in smooth muscle and neutrophils
3. Distinct and specific functions of cGMP-dependent protein kinases
4. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase 1α
5. Rising behind NO: cGMP-dependent protein kinases
6. Defective smooth muscle regulation in cGMP kinase I-deficient mice
7. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects
8. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody
9. The role of nitric oxide and other endothelium-derived vaso-active substances in vascular disease
10. Hypercholesterolemia increases endothelial superoxide anion production
11. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits
12. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin- angiotensin system
13. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion
14. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis
15. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia
16. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice
17. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance
18. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production
19. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability
20. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors
21. Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine. Implications for cystic fibrosis transmembrane conductance regulator
22. VASP
23. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance
24. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators
25. The 46/50 kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts
26. Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin
27. Expression of cGMP-dependent protein kinase 1 and its substrate VASP in neointimal cells of the injured rat carotid artery
28. Reconstitution of actin-based motility of Listeria and Shigella using pure proteins
29. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function
30. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice
31. The vasodilator-stimulated phosphoprotein (VASP): Target of YC-1 and nitric oxide effects in human and rat platelets
32. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
33. Peroxynitrite stimulates vascular smooth muscle cell cyclic GMP synthesis
34. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process
35. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors
36. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: Key role of L-arginine availability
37. Superoxide and peroxynitrite in atherosclerosis
38. Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function
39. 1 receptor expression by hypercholesterolemia
40. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
41. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells